November 28, 2016 - By Winifred Garcia
Judy Brown, EVP – Business Ops & CFO of Perrigo Co Plc, in an insider selling transaction sold 2,097 shares whose amount is estimated to be $187,556 at average stock price of $89.4. The trade was unveiled in a filing filed with the Washington-based SEC on November 28, 2016, which is available for free access here. This sell decreased her ownership of Perrigo Co Plc to 0.01% total market capitalization or 10,007 shares.
Out of 15 analysts covering Perrigo Company Plc (NYSE:PRGO), 4 rate it a “Buy”, 1 “Sell”, while 10 “Hold”. This means 27% are positive. $241 is the highest target while $84 is the lowest. The $128.45 average target is 45.65% above today’s ($88.19) stock price. Perrigo Company Plc has been the topic of 35 analyst reports since October 23, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Thursday, August 11 by JP Morgan. As per Monday, April 25, the company rating was downgraded by BTIG Research. The stock of Perrigo Company plc Ordinary Shares (NYSE:PRGO) earned “Hold” rating by Jefferies on Thursday, August 11. The stock of Perrigo Company plc Ordinary Shares (NYSE:PRGO) has “Hold” rating given on Monday, June 20 by Argus Research. B. Riley & Co downgraded the shares of PRGO in a report on Friday, February 19 to “Neutral” rating. The firm earned “Buy” rating on Thursday, December 10 by Argus Research. The firm earned “Neutral” rating on Friday, November 11 by Bank of America. The firm has “Buy” rating given on Friday, October 23 by Deutsche Bank. The company was maintained on Tuesday, April 26 by JP Morgan. The stock of Perrigo Company plc Ordinary Shares (NYSE:PRGO) earned “Equal-Weight” rating by Morgan Stanley on Thursday, December 3.
Insitutional Activity: The institutional sentiment decreased to 0.77 in Q2 2016. Its down 0.04, from 0.81 in 2016Q1. The ratio dropped, as 102 funds sold all Perrigo Company plc Ordinary Shares shares owned while 173 reduced positions. 80 funds bought stakes while 142 increased positions. They now own 86.20 million shares or 12.38% less from 98.38 million shares in 2016Q1.
Manning Napier Advsr Limited Liability last reported 2.26 million shares in the company. North Run Cap Lp accumulated 465,000 shares or 6.95% of the stock. Millennium Mngmt Lc holds 489,818 shares or 0.1% of its portfolio. Washington Natl Bank, a Washington-based fund reported 36 shares. Royal Bancorporation Of Canada holds 94,448 shares or 0.01% of its portfolio. Macquarie Gru holds 84,224 shares or 0.01% of its portfolio. Livforsakringsbolaget Skandia Omsesidigt accumulated 0.05% or 13,163 shares. Washington Tru reported 137,755 shares or 0.84% of all its holdings. Edge Asset Mngmt Inc last reported 0.08% of its portfolio in the stock. Thornburg Mngmt owns 568,838 shares or 0.4% of their US portfolio. Cornerstone Cap Mngmt Ltd Co has 547,968 shares for 2.62% of their US portfolio. Creative Planning accumulated 0% or 3,023 shares. Amica Retiree Med Trust accumulated 0.09% or 1,157 shares. Dubuque Bank & Trust owns 79 shares or 0% of their US portfolio. The New York-based Glob X Communications Ltd Llc has invested 0% in Perrigo Company plc Ordinary Shares (NYSE:PRGO).
Insider Transactions: Since August 26, 2016, the stock had 1 insider purchase, and 7 sales for $1.15 million net activity. $189,159 worth of Perrigo Company plc Ordinary Shares (NYSE:PRGO) was sold by Brown Judy L. Another trade for 5,814 shares valued at $522,974 was sold by KUNKLE GARY K JR. KINGMA TODD W sold $66,512 worth of Perrigo Company plc Ordinary Shares (NYSE:PRGO) on Monday, November 21. $107,404 worth of Perrigo Company plc Ordinary Shares (NYSE:PRGO) was sold by Farrington Thomas. MORRIS HERMAN JR had sold 1,073 shares worth $97,595. 2,500 shares were bought by Parker Geoffrey M., worth $221,875 on Monday, November 21.
The stock increased 0.40% or $0.35 during the last trading session, hitting $88.19. About 1.70M shares traded hands. Perrigo Company plc Ordinary Shares (NYSE:PRGO) has declined 11.63% since April 25, 2016 and is downtrending. It has underperformed by 17.64% the S&P500.
According to Zacks Investment Research, “Perrigo Company plc develops, manufactures and distributes healthcare products. The company operates primarily in four segments: Consumer Healthcare, Nutritionals, Rx Pharmaceutical and Active Pharmaceutical Ingredients. It also provides animal health products. The company operates primarily in the United States, the United Kingdom, Mexico, Israel, Australia, Canada, China and Latin America. Perrigo Company plc formerly known as Perrigo Company is headquartered in Ireland.”
Analysts await Perrigo Company plc Ordinary Shares (NYSE:PRGO) to report earnings on February, 16. They expect $1.67 earnings per share, down 7.22% or $0.13 from last year’s $1.8 per share. PRGO’s profit will be $238.41 million for 13.20 P/E if the $1.67 EPS becomes a reality. After $1.65 actual earnings per share reported by Perrigo Company plc Ordinary Shares for the previous quarter, Wall Street now forecasts 1.21% EPS growth.
More news for Perrigo Company plc Ordinary Shares (NYSE:PRGO) were recently published by: Fool.com, which released: “Why Perrigo Company PLC Ordinary Shares Are Dropping Today” on April 25, 2016. Fool.com‘s article titled: “Why Perrigo Company PLC Ordinary Shares Are Plummeting Today” and published on February 18, 2016 is yet another important article.
Perrigo Company plc (Perrigo), formerly Perrigo Company Limited, incorporated on June 28, 2013, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company’s divisions include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx), Specialty Sciences and Other. The Firm makes OTC healthcare products and supplies infant formulas for the store brand market. It is also a well-known provider of generic extended topical prescription products. It provides healthcare products across a range of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.